Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Online Videos | News | Weblinks | Medicines | Pharmacy | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options: See related products available from our registered pharmacy AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Steroids and the Skin

Topical corticosteroids have been used for about 50 years and their introduction was a milestone in dermatology. They are used to treat inflammatory skin conditions by suppressing the inflammatory reaction and relieving symptoms. However, they are not curative and attempts to increase potency have often been associated with more adverse effects. The emphasis should be on limited, selective, and careful use with clear explanation and instruction to patients.

Indications
  • Eczema - the most important because it is very common both in adults and children (affecting 15-20% of school children and 2-10% of adults). Children are most at risk from misuse and adverse effects. See Atopic eczema article.
  • Contact dermatitis
  • Seborrhoeic dermatitis
  • Insect stings
  • Eczema associated with infection - with caution
  • Psoriasis - with caution
  • Other inflammatory skin conditions including: discoid lupus erythematosus; lichen planus under specialist supervision.
Evidence of efficacy
  • Randomized controlled trials (RCTs) show treatment effect over placebo for atopic eczema.1
  • There is consensus that topical steroids are effective for seborrhoeic dermatitis of the scalp in adults.2 There were however no RCTs comparing steroids.
  • Short courses of steroids used episodically are effective by consensus, for treating seborrhoeic dermatitis of the face and body in adults.3
  • In psoriasis evidence of potent steroid efficacy similar to vitamin D derivatives is available but evidence of side effects and flares of the disease on withdrawal were also found. 4,5,6
Pre-prescribing assessment and investigation
  • Establish correct diagnosis. Does the lesion fit diagnostic criteria of, for example atopic eczema?7
  • Consider diagnoses which require different treatment approach. For example: scabies, bacterial infection (suggested by crusting and weeping) herpes infection (suggested by vesicles or punched out erosions).
  • Consider wider management issues:
    • Aggravating factors
    • Previous treatments
    • Impact on quality of life
    • Other medications
    • Growth chart in children
When should referral be considered?

Referral might be considered, occasionally before treatment if:

  • Diagnosis unclear
  • Certain diagnoses where distribution and severity require referral
  • Severe infection suspected e.g. eczema herpeticum
  • Lack of response to treatment of primary condition (see guidance below)
  • Failure of treatment for secondary infection
  • Contact dermatitis requiring patch testing suspected
  • Additional advice or treatments required
  • Dietary factors suspected
Starting, monitoring and further guidance on use of topical steroids

Anecdotally and within articles written about use of topical steroids there are a number of common criticisms, implied or overt, of general practitioner's prescribing of topical steroids.8,9,10 This may reflect what is seen by specialists receiving referrals rather than what is going on more widely. Criticism includes:

  • Prescribing inappropriate quantities. Usually quantities prescribed are too small.
  • Prescribing an inappropriate strength of steroid and length of treatment. (The BNF classifies topical steroids as mild, moderate and potent).
  • Prescribing emollients inadequately. These are not prescribed often enough, in sufficient quantity or with correct instructions.
  • Prescribing generally with inadequate instructions in the use of both emollients and topical steroids.

Guidance has been issued with this in mind.7,11 There may be a place for use of printed information (Including detail of how to use emollients and topical steroids) and education involving practice nurses to help improve efficacy of treatments and information for patients. Examples can be obtained from the British Association of Dermatologists7 and the National Eczema Society.

Guidance can be summarized as follows:

  • Choice of formulation is important. Creams are best for weeping or moist areas and ointments for dry scaly or lichenified areas. Lotions are useful for larger or hair bearing areas. Occlusive dressings increase absorption. Caution and close supervision is required.
  • Potency of steroid should be matched to disease severity and site. For example:
    • Face, genitals and flexures. Skin is thin and self occludes within the skin fold, thus increasing absorption. Milder steroids should therefore be prescribed.
    • Eyelids. Skin is thin. Restrict to intermittent mild steroid for no more than 14 days and avoid eye contact. Over age 35 beware risk of glaucoma if used for more than 14 days and monitor IOPs.
    • Palms, soles of feet and scalp. Skin is thicker. Stronger steroids required.
    • Children. Use weaker steroids especially when large area to be treated. Consider specialist referral if moderate strength steroids are needed to maintain control.
    • Trunk and limbs in adults. Use weakest strength required to achieve control within 14 days as judged by severity of the inflammation and prior response to treatment.
  • Treatment gives only symptomatic relief and duration of treatment should be limited to a week for acute conditions and 4-6 weeks to achieve remission in, for example, chronic eczema.
  • Short bursts of stronger steroids can be used to gain control over a few days.12
  • Specific guidance on how much cream or ointment should be prescribed is helpful. For example, a guide to quantities from the BNF for an acute eczema flare up in adults is:

    Face and neck 30g
    Both hands 30g
    Scalp 30g
    Both arms 60g
    Both legs 100g
    Trunk 100g
    Groin and genitalia 30g

  • Give specific information on the quantity to be applied (as too much risks side effects and too little may be ineffective). This can be specified according to the calculation that one FTU (finger tip unit, or length squeezed from tube between tip of finger and first skin crease) is enough to cover an area about twice the area of the palmar aspect of the hand (and weighs approximately 500 mg).
  • No more than twice daily should be applied and the NICE guidelines13 suggest that once daily may be as effective as more frequent applications. This may also reduce side effects.
  • Topical steroids should not be used for emollient effect. Emollients should be applied at least 30 minutes before the topical steroid. Frequent and intensive emollient use in eczema will reduce the amount of steroid needed.
  • Regular review of treatment should be undertaken to ensure that minimum strength required is being used and to check for side effects. Care should be taken to follow up more closely use of stronger steroids, children, and in areas of the body where skin is thin.
  • Immunomodulatory agents such as tacrolimus and pimeecrolimus are now available as an alternative to topical steroids. These are as effective but more expensive. Initiation usually requires referral.
Cautions/contraindications

Topical corticosteroids are contraindicated in:

They should be used with caution in children, certain sites (see below) and psoriasis.

Common side effects

These may be systemic or local.14,15,16

  • Systemic side effects are more likely with more potent steroids, larger quantities, more frequent application and where absorption is greatest (certain sites of the body and occlusion enhance absorption). Safe weekly limits to avoid systemic side effects have been suggested:17

    Treatment period in months Mild to moderate Potent Very potent
    Less than 2 months 100g 50g 30g
    2-6 months 50g 30g 15g
    6-12 months 25g 15g 7.5g

  • Children by virtue of skin type, surface area to weight ratio and disease severity are more at risk of systemic side effects and should be monitored closely. The risk of growth retardation exists and growth should be monitored under specialist supervision where moderate strength steroids are required regularly.
  • Localized adverse effects such as skin thinning are unlikely to occur in less than 4 weeks in mild to moderate strength steroids but can occur with potent steroid within 1-3 weeks. This will reverse within 4 weeks if stopped. If potent steroids are required for control of inflammation for more than 7 days in a 5 week period referral is recommended because of the risk of local side effects.11
    Local side effects include:
    • Spreading infection
    • Depigmentation
    • Skin thinning
    • Striae
    • Telangiectasia
    • Contact dermatitis
    • Perioral dermatitis
    • Acne
    • Acne rosacea
  • Avoidance of infection may be promoted by steroid-antibiotic combinations (evidence lacking), emollient antimicrobial preparations, not leaving tubs open, pump dispensers, general hand hygiene measures.

Document references
  1. Hoare C, Li Wan Po A, Williams H; Systematic review of treatments for atopic eczema.; Health Technol Assess. 2000;4(37):1-191. [abstract]
  2. Gupta AK, Bluhm R, Cooper EA, et al; Seborrheic dermatitis.; Dermatol Clin. 2003 Jul;21(3):401-12. [abstract]
  3. Clinical Evidence; Topical steroids in seborrhoeic dermatitis; [Subscription required]
  4. Mason J, Mason AR, Cork MJ; Topical preparations for the treatment of psoriasis: a systematic review.; Br J Dermatol. 2002 Mar;146(3):351-64. [abstract]
  5. Katz HI, Prawer SE, Medansky RS, et al; Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen.; Dermatologica. 1991;183(4):269-74. [abstract]
  6. Kragballe K, Barnes L, Hamberg KJ, et al; Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy.; Br J Dermatol. 1998 Oct;139(4):649-54. [abstract]
  7. British Association of Dermatologists, guidelines
  8. Long CC, Funnell CM, Collard R, et al; What do members of the National Eczema Society really want?; Clin Exp Dermatol. 1993 Nov;18(6):516-22. [abstract]
  9. Long CC, Finlay AY; Perceived underprescription of topical therapy.; Br J Gen Pract. 1993 Jul;43(372):305.
  10. Gibson N, Ferguson JW; Steroid cover for dental patients on long-term steroid medication: proposed clinical guidelines based upon a critical review of the literature.; Br Dent J. 2004 Dec 11;197(11):681-5. [abstract]
  11. Eczema - atopic, Clinical Knowledge Summaries (2004)
  12. Charman C, Williams H; The use of corticosteroids and corticosteroid phobia in atopic dermatitis.; Clin Dermatol. 2003 May-Jun;21(3):193-200.
  13. Atopic dermatitis (eczema) - topical steroids, NICE (2004); Ref TA81
  14. Hengge UR, Ruzicka T, Schwartz RA, et al; Adverse effects of topical glucocorticosteroids.; J Am Acad Dermatol. 2006 Jan;54(1):1-15; quiz 16-8. [abstract]
  15. Brazzini B, Pimpinelli N; New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use.; Am J Clin Dermatol. 2002;3(1):47-58. [abstract]
  16. Hoffmann K, Auer T, Stucker M, et al; Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.; J Eur Acad Dermatol Venereol. 1998 Mar;10(2):137-42. [abstract]
  17. Coulson I, 1996 Topical Steroids for Skin Disease Dermatology In Practice March/April 5-8
AcknowledgementsEMIS is grateful to Dr Richard Draper for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 33
Document Version: 3
DocRef: bgp25026
Last Updated: 24 Aug 2007
Review Date: 23 Aug 2008






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page